Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis.

IMPORTANCE Hydroxyethyl starch is commonly used for volume resuscitation yet has been associated with serious adverse events, including acute kidney injury and death. Clinical trials of hydroxyethyl starch are conflicting. Moreover, multiple trials from one investigator have been retracted because of scientific misconduct. OBJECTIVES To evaluate the association of hydroxyethyl starch use with mortality and acute kidney injury. DATA SOURCES Randomized controlled trials from MEDLINE, EMBASE, CENTRAL, Global Health, HealthStar, Scopus, Web of Science, the International Clinical Trials Registry Platform (inception to October 2012), reference lists of relevant articles, and gray literature. STUDY SELECTION Two reviewers independently identified randomized controlled trials comparing hydroxyethyl starch with other resuscitation fluids in critically ill patients receiving acute volume resuscitation. DATA EXTRACTION Two reviewers independently extracted trial-level data including population characteristics, interventions, outcomes, and funding sources. Risk of bias was assessed using the risk of bias tool; the strength of evidence was adjudicated using the GRADE methodology. RESULTS We included 38 eligible trials comparing hydroxyethyl starch to crystalloids, albumin, or gelatin. The majority of trials were categorized as having an unclear risk or high risk of bias. For the 10,880 patients in studies contributing mortality data, the risk ratio (RR) for death among patients randomized to receive hydroxyethyl starch was 1.07 (95% CI, 1.00 to 1.14; I2, 0%; absolute risk [AR], 1.20%; 95% CI, -0.26% to 2.66%). This summary effect measure included results from 7 trials performed by an investigator whose subsequent research had been retracted because of scientific misconduct. When we excluded these 7 trials that involved 590 patients, hydroxyethyl starch was found to be associated with increased mortality among 10,290 patients (RR, 1.09; 95% CI, 1.02 to 1.17; I2, 0%; AR, 1.51%; 95% CI, 0.02% to 3.00%), increased renal failure among 8725 patients (RR, 1.27; 95% CI, 1.09 to 1.47; I2, 26%; AR, 5.45%; 95% CI, 0.44% to 10.47%), and increased use of renal replacement therapy among 9258 patients (RR, 1.32; 95% CI, 1.15 to 1.50; I2, 0%; AR, 3.12%; 95% CI, 0.47% to 5.78%). CONCLUSION AND RELEVANCE In critically ill patients requiring acute volume resuscitation, use of hydroxyethyl starch compared with other resuscitation solutions was not associated with a decrease in mortality. Moreover, after exclusion of 7 trials performed by an investigator whose research has been retracted because of scientific misconduct, hydroxyethyl starch was associated with a significant increased risk of mortality and acute kidney injury. Clinical use of hydroxyethyl starch for acute volume resuscitation is not warranted due to serious safety concerns.

[1]  G. Hempelmann,et al.  The Effects of Albumin Versus Hydroxyethyl Starch Solution on Cardiorespiratory and Circulatory Variables in Critically III Patients , 1996, Anesthesia and analgesia.

[2]  D. Birolini,et al.  Use of Pentastarch Solution in the Treatment of Patients with Hemorrhagic Hypovolemia: Randomized Phase II Study in the Emergency Room , 1998, World Journal of Surgery.

[3]  K. Nagy,et al.  A comparison of pentastarch and lactated Ringer's solution in the resuscitation of patients with hemorrhagic shock. , 1993, Circulatory shock.

[4]  J. Tenhunen,et al.  Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. , 2012, The New England journal of medicine.

[5]  C. Natanson,et al.  Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses , 2012, Intensive Care Medicine.

[6]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[7]  P. Gosling,et al.  Hydroxyethylstarch supplementation in burn resuscitation--a prospective randomised controlled trial. , 2010, Burns : journal of the International Society for Burn Injuries.

[8]  G. Hempelmann,et al.  Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. , 1996, Critical care medicine.

[9]  T. Neff,et al.  Pharmacokinetics of Hydroxyethyl Starch , 2005, Clinical pharmacokinetics.

[10]  P. Coriat,et al.  Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients , 1996, The Lancet.

[11]  Q. Xia,et al.  Hydroxyethyl Starch Resuscitation Reduces the Risk of Intra-Abdominal Hypertension in Severe Acute Pancreatitis , 2011, Pancreas.

[12]  G. Hempelmann,et al.  Influence of different volume therapy regimens on regulators of the circulation in the critically ill. , 1996, British journal of anaesthesia.

[13]  J. Bromilow,et al.  Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis , 2013 .

[14]  Chunmao Han,et al.  [Evaluation of effectiveness and safety of a new hydroxyethyl starch used in resuscitation of burn shock]. , 2006, Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns.

[15]  W. Padberg,et al.  Does the type of volume therapy influence endothelial-related coagulation in the critically ill? , 1995, British journal of anaesthesia.

[16]  J. Verheij,et al.  Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia* , 2009, Critical care medicine.

[17]  P Rama-Maceiras,et al.  [Fraudulent pain research: a hurt so deep nothing can alleviate it]. , 2009, Revista espanola de anestesiologia y reanimacion.

[18]  J. Bérard,et al.  Hydroxyéthylamidons Versus Gélatines: Impact Sur Le Coût Du Remplissage Dans Un Service De Réanimation , 1995 .

[19]  R. Bellomo,et al.  Hydroxyethyl starch or saline for fluid resuscitation in intensive care. , 2012, The New England journal of medicine.

[20]  L. Brochard,et al.  Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study , 2001, The Lancet.

[21]  G. Hempelmann,et al.  Volume therapy in the critically ill: is there a difference? , 1998, Intensive Care Medicine.

[22]  Rolf Rossaint,et al.  Intensive insulin therapy and pentastarch resuscitation in severe sepsis. , 2008, The New England journal of medicine.

[23]  B. Erstad,et al.  A Paradigm for Consensus: The University Hospital Consortium Guidelines for the Use of Albumin, Nonprotein Colloid, and Crystalloid Solutions , 1995 .

[24]  S. Finfer,et al.  Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. , 2012, Anesthesia and analgesia.

[25]  T. Szakmany,et al.  Fluid resuscitation with colloids of different molecular weight in septic shock , 2004 .

[26]  W. Padberg,et al.  The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients , 1996, Anaesthesia.

[27]  M. Weil,et al.  Effects of Hetastarch and Albumin on Coagulation in Patients with Septic Shock , 1988, Journal of clinical pharmacology.

[28]  C. Mecher,et al.  Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. , 1989 .

[29]  P. Asfar,et al.  Assessment of hemodynamic and gastric mucosal acidosis with modified fluid gelatin versus 6% hydroxyethyl starch: a prospective, randomized study , 2000, Intensive Care Medicine.

[30]  Hui-ying Zhao,et al.  [The influence of lactate Ringer solution versus hydroxyethyl starch on coagulation and fibrinolytic system in patients with septic shock]. , 2012, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[31]  B. Erstad,et al.  A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. , 1995, Archives of internal medicine.

[32]  D. Cook,et al.  Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials , 2009, Open medicine : a peer-reviewed, independent, open-access journal.

[33]  A. Wakefield,et al.  Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. , 1998, Lancet.

[34]  M. Flaig,et al.  Hydroxyethyl starch‐induced itch: Relevance of light microscopic analysis of semi‐thin sections and electron microscopy , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[35]  Gilles Clermont,et al.  RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis , 2006, Critical care.

[36]  P. Navsaria,et al.  Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). , 2011, British journal of anaesthesia.

[37]  Attila Havas,et al.  Short-term effectiveness of different volume replacement therapies in postoperative hypovolaemic patients , 2010, European journal of anaesthesiology.

[38]  P. Svoboda,et al.  Therapeutic influence of 20 % albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial. , 2009, Hepato-gastroenterology.

[39]  C. Ince,et al.  Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. , 2010, Journal of critical care.

[40]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[41]  Feng Li,et al.  [The effect of different fluids on early fluid resuscitation in septic shock]. , 2008, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[42]  G. Hempelmann,et al.  Influence of different volume therapies on platelet function in the critically ill , 1996, Intensive Care Medicine.

[43]  D. Cook,et al.  Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial , 2008, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[44]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[45]  T. Lancet,et al.  Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children , 2010, The Lancet.

[46]  J. Edwards,et al.  Comparison of the hemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill Patients: A prospective, randomized trial , 1994, Critical care medicine.

[47]  W. Jurecka,et al.  Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. , 1999, British journal of anaesthesia.

[48]  J. Carlisle,et al.  The analysis of 168 randomised controlled trials to test data integrity , 2012, Anaesthesia.

[49]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[50]  Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin, and saline solutions , 1982, Critical care medicine.

[51]  Yong-sheng Shao,et al.  [The study of hypertonic saline and hydroxyethyl starch treating severe sepsis]. , 2011, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[52]  Jonathan J Deeks,et al.  Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events , 2007, Statistics in medicine.

[53]  P. Perel,et al.  Colloids versus crystalloids for fluid resuscitation in critically ill patients. , 2013, The Cochrane database of systematic reviews.

[54]  J. Heltne,et al.  Capillary leakage in post-cardiac arrest survivors during therapeutic hypothermia - a prospective, randomised study , 2010, Scandinavian journal of trauma, resuscitation and emergency medicine.

[55]  T. Veneman,et al.  Human albumin and starch administration in critically ill patients: A prospective randomized clinical trial , 2004, Wiener Klinische Wochenschrift.

[56]  M. Inal,et al.  Effects of polygeline and hydroxyethyl starch solutions on liver functions assessed with LIMON in hypovolemic patients. , 2010, Journal of critical care.

[57]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[58]  T. Randell,et al.  Peroperative fluid management of the brain‐dead multiorgan donor , 1990, Acta anaesthesiologica Scandinavica.

[59]  Tsuguya Fukui,et al.  Systematic Evaluation and Comparison of Statistical Tests for Publication Bias , 2005, Journal of epidemiology.

[60]  P. Rama-Maceiras,et al.  Algología fraudulenta. Un dolor demasiado profundo para una adecuada analgesia , 2009 .

[61]  B. Guidet,et al.  Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study , 2012, Critical Care.

[62]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[63]  Abstracts of the 9th Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA). April 12-16, 2011. Cape Town, South Africa. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[64]  P. Alderson,et al.  Colloid solutions for fluid resuscitation. , 2003, The Cochrane database of systematic reviews.

[65]  G. Orliaguet,et al.  Remplissage vasculaire préhospitalier en traumatologie: Hesteril® 6 % versus Plasmion® , 2000 .